Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ballantyne

Showing results (441-450 of 999) with videos related to

Pageof 100
Sort By:
Diabetes Care|July 27, 2005
Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities studyMaria Inês Schmidt, Bruce B Duncan, Heejung Bang, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 23, 2011
Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD studyL Maria Belalcazar, Christie M Ballantyne, Wei Lang, et al.
Diabetes Care|January 29, 2005
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities studyAnn Marie McNeill, Wayne D Rosamond, Cynthia J Girman, et al.
Kidney International|September 4, 2017
Plasma galectin-3 levels are associated with the risk of incident chronic kidney diseaseCasey M Rebholz, Elizabeth Selvin, Menglu Liang, et al.
Journal of Clinical Lipidology|January 15, 2013
Non-high-density lipoprotein cholesterol reporting and goal attainment in primary careSalim S Virani, Degang Wang, LeChauncy D Woodard, et al.
Journal of the American Heart Association|March 17, 2023
Growth Differentiation Factor 15 and Risk of Bleeding Events: The Atherosclerosis Risk in Communities StudyLena Mathews, Xiao Hu, Ning Ding, et al.
Circulation. Cardiovascular Genetics|November 3, 2012
Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapyAudrey Y Chu, Franco Guilianini, Harald Grallert, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 3, 2015
Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective studyXuemei Huang, Alvaro Alonso, Xuguang Guo, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
cpiVAE: Robust and Interpretable Cross-Platform Proteomics ImputationYuxiang Li, ThuyVy Duong, Mary R Rooney, et al.
The American Journal of Cardiology|August 1, 1997
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])J A Herd, C M Ballantyne, J A Farmer, et al.
Pageof 100

Showing results (441-450 of 999) with videos related to

Sort By:
Pageof 100
Diabetes Care|July 27, 2005
Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities studyMaria Inês Schmidt, Bruce B Duncan, Heejung Bang, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 23, 2011
Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD studyL Maria Belalcazar, Christie M Ballantyne, Wei Lang, et al.
Diabetes Care|January 29, 2005
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities studyAnn Marie McNeill, Wayne D Rosamond, Cynthia J Girman, et al.
Kidney International|September 4, 2017
Plasma galectin-3 levels are associated with the risk of incident chronic kidney diseaseCasey M Rebholz, Elizabeth Selvin, Menglu Liang, et al.
Journal of Clinical Lipidology|January 15, 2013
Non-high-density lipoprotein cholesterol reporting and goal attainment in primary careSalim S Virani, Degang Wang, LeChauncy D Woodard, et al.
Journal of the American Heart Association|March 17, 2023
Growth Differentiation Factor 15 and Risk of Bleeding Events: The Atherosclerosis Risk in Communities StudyLena Mathews, Xiao Hu, Ning Ding, et al.
Circulation. Cardiovascular Genetics|November 3, 2012
Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapyAudrey Y Chu, Franco Guilianini, Harald Grallert, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 3, 2015
Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective studyXuemei Huang, Alvaro Alonso, Xuguang Guo, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
cpiVAE: Robust and Interpretable Cross-Platform Proteomics ImputationYuxiang Li, ThuyVy Duong, Mary R Rooney, et al.
The American Journal of Cardiology|August 1, 1997
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])J A Herd, C M Ballantyne, J A Farmer, et al.
Pageof 100